Overview

Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI

Status:
Not yet recruiting
Trial end date:
2024-04-15
Target enrollment:
Participant gender:
Summary
The purpose of the research is to determine whether a medication called dapagliflozin will improve the heart's function and reduce its enlargement after a heart attack. Participation in this study will involve taking the medication dapagliflozin (or a placebo) once daily for six months, one cardiac magnetic resonance imaging (MRI) test during your initial hospitalization, follow-up phone calls at 1 and 3 months, and one cardiac MRI and clinic visit at six months.
Phase:
Phase 2
Details
Lead Sponsor:
Minneapolis Heart Institute Foundation
Treatments:
Dapagliflozin